Vorasidenib: Patient and caregiver information sheet
Neurooncol Pract
.
2024 Nov 25;12(Suppl 1):i26-i28.
doi: 10.1093/nop/npae081.
eCollection 2025 Feb.
Authors
Mallika P Patel
1
2
,
Jennifer N Serventi
3
,
Erin M Dunbar
4
,
Kathy Oliver
5
,
Karin Piil
6
,
Tatjana Seute
7
,
Susan Chang
8
Affiliations
1
Department of Pharmacy, Duke University Medical Center, Durham, North Carolina, USA.
2
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA.
3
Department of Neurology, Neuro-Oncology, University of Rochester Medical Center, Rochester, New York, USA.
4
Piedmont Physicians Neuro Oncology, Piedmont Atlanta Hospital, Atlanta, Georgia, USA.
5
International Brain Tumor Alliance (IBTA), Tadworth, Surrey, UK.
6
Department of People and Technology, Roskilde University, Roskilde, Denmark.
7
Department of Neuro-oncology, UMC Utrecht, Utrecht, The Netherlands.
8
Neurological Surgery, UCSF Weill Institute for Neurosciences, San Francisco, California, USA.
PMID:
39776531
PMCID:
PMC11703360
(available on
2025-11-25
)
DOI:
10.1093/nop/npae081
No abstract available
Keywords:
IDH-mutant gliomas; patient education.
Publication types
Review